The mRNA Vaccines and Therapeutics Market is estimated at $3.43 billion in 2018. The Standardized Therapeutic Cancer mRNA Vaccines segment held a share of 35.47% in 2018 and is projected to grow with a CAGR of 9.77% in next ten years.
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 184-page report you will receive 130 charts– all unavailable elsewhere.
The 184-page report provides clear detailed insight into the mRNA Vaccines and Therapeutics Market. Discover the key drivers and challenges affecting the market.
Report Scope
• Revenue and growth forecasts from 2019 to 2029 for the mRNA Vaccines and Therapeutics market
• Revenue and growth forecasts from 2019 to 2029 for the mRNA Vaccines and Therapeutics market by type: • Standardized Therapeutic Cancer mRNA Vaccines • Individualized Therapeutic Cancer mRNA Vaccines • Therapeutic Infectious Disease mRNA Vaccines • mRNA Therapeutic for Other Diseases
• Revenue and growth forecasts from 2019 to 2029 for the mRNA Vaccines and Therapeutics market by Mechanism of Action: • Bioengineered Vaccine • Gene Therapy (Gene Silencing/Suppression) • Gene Transcription (Protein Generation) • Cell Therapy • Monoclonal Antibody • Others
• Revenue and growth forecasts from 2019 to 2029 for the leading regional and national markets: • North America: the revenues are further broken down into the US and Canada • Europe: the revenues are further broken down into the UK, Germany, France, Italy and Spain • Asia-Pacific: the revenues are further broken down into China, Japan and India • Rest of the World: the revenues are further broken down into Brazil, Mexico, Russia and South Africa
• Discussion and profiles of the leading players in the mRNA Vaccines and Therapeutics market: • Argos Therapeutics, Inc. • BioNTech AG • CureVac AG • eTheRNA Immunotherapies • ethris GmbH • In-Cell-Art • Moderna Therapeutics • Sangamo Therapeutics, Inc. • Tiba Biotech • Translate Bio, Inc.
• Qualitative analysis of factors that drive and restrain the mRNA Vaccines and Therapeutics market. Trends analysis of the mRNA Vaccines and Therapeutics market.
• mRNA Vaccines and Therapeutics R&D pipeline analysis
• Key Questions Answered by this Report: • How is the mRNA vaccines and therapeutics market evolving? • What is driving and restraining the mRNA vaccines and therapeutics market? • What are the market shares of the leading segments of the mRNA vaccines and therapeutics market in 2018? • What will be the main driver of the overall market from 2019 to 2029? • How will the market shares of the leading national markets change by 2029 and which country will lead the market in 2029? • How will the industry evolve during the period between 2019 and 2029? • Who are the leading companies in this market?
Visiongain’s study is intended for anyone requiring commercial analyses for the mRNA Vaccines and Therapeutics market. You find data, trends and predictions.
Buy our report today mRNA Vaccines and Therapeutics Market : Standardized Therapeutic Cancer mRNA Vaccines, Individualized Therapeutic Cancer mRNA Vaccines, Therapeutic Infectious Disease mRNA Vaccines, mRNA Therapeutic for Other Diseases, Bioengineered Vaccine, Gene Transcription, Monoclonal Antibody, Gene Therapy, Cell Therapy.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview
1.1 Global mRNA Vaccines and Therapeutics Market Overview
1.2 Global mRNA Vaccines and Therapeutics Market Segmentation
1.3 Overview of Findings
1.4 Structure of the Report
1.5 Why You Should Read This Report
1.6 How This Report Delivers
1.7 Main Questions Answered by this Report
1.8 Who is this Report for?
1.9 Research and Analysis Methods
1.10 Frequently Asked Questions (FAQ)
1.11 Associated Reports
1.12 About Visiongain
2. Introduction to mRNA Vaccines and Therapeutics
2.1 History of mRNA Vaccines & Therapeutics Development
2.2 Incidence and Prevalence of Chronic Diseases and Major Infectious Diseases
2.3 Prevention and Treatment Using mRNA Vaccines & Therapeutics
2.3.1 mRNA Modifications
2.3.2 mRNA Efficiencies
2.3.3 Adjuvant/Stimulant & Carrier Technologies for mRNA-based Vaccines
2.3.4 Carriers for mRNA-based Protein & Antibody Therapeutics
3. Introduction of mRNA & Delivery Technologies
3.1 Ex vivo mRNA Loading
3.1.1 Arcelis Technology
3.1.2 Flow Electroporation Technology
3.2 In vivo Carrier & mRNA
3.2.1 Hybrid mRNA Technology
3.2.2 Lipid Nanoparticle (LNP) mRNA Technology
3.2.3 Nanotaxi Technology
3.2.4 RNArt & RNAntibody Technology
3.2.5 UNA & LUNAR Technologies
3.3 mRNA Vaccines & Stimulants / Adjuvants
3.3.1 RNActive Technology
3.3.2 Self-Amplifying mRNA (SAM) Technology
3.3.3 TriMix Technology
4. Global mRNA Vaccines & Therapeutics: Market Size and Forecast 2019-2029
4.1 mRNA Vaccines and Therapeutics Market Overview, 2018
4.2 The World mRNA Vaccines and Therapeutics Market
4.3 World mRNA Vaccines and Therapeutics Market: Sales Forecast 2019-2029
4.4 Changing Market Shares by Region 2018-2029
5. mRNA Vaccines and Therapeutics Market: Drivers, Restraints, and Trends Analysis 2019-2029
5.1 mRNA Vaccines and Therapeutics Market: Drivers 2019-2029
5.1.1 Rising Adoption of Personalized Medicine for Effective Treatment
5.1.2 Advantages Offered by mRNA-based Products
5.1.3 Rising Funding by Pharmaceutical Companies and Government Organizations
5.2 mRNA Vaccines and Therapeutics Market: Restraints 2019-2029
5.2.1 Delivery of mRNA therapeutics and vaccines
5.2.2 Stringent Government Regulations for mRNA-based Product Approvals
5.3 mRNA Vaccines and Therapeutics Market: Trends 2019-2029
5.3.1 Rising adoption of gene therapy-based products
6. mRNA Vaccines & Therapeutics by Type: Market Size and Forecast 2019-2029
6.1 Market Forecast 2019-2029
6.2 Market Share of mRNA Vaccines and Therapeutics by Type
6.2.1 Standardized Therapeutic Cancer mRNA Vaccines: Market Forecast, 2019-2029
6.2.2 Individualized Therapeutic Cancer mRNA Vaccines: Market Forecast, 2019-2029
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
The global single cell analysis market was valued at US$3,255.0 million in 2022 and is projected to grow at a CAGR of 15.1% during the forecast period 2022-2032.
The number of people who are blind or have poor vision is expected to rise considerably in the coming years. The growing elderly population is one of the key drivers of the Ophthalmic Devices Market’s upward trend.
The growing global health system has made significant contributions to protecting and promoting human health. However, long-standing, developing, and reemerging infectious disease risks continue to plague the planet
The major driving factor contributing towards the growth of pharmaceutical contract manufacturing market are increase in investments in pharmaceutical R&D, rise in number of patent expiry, rising demand of generic drugs, and investment in advanced manufacturing technologies. However, use of serialization can thwart the market growth.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
